News

In the United States, Tasigna is now indicated for the treatment of adult and pediatric patients one year of age or older with newly diagnosed Ph+ CML-CP. Tasigna

The company said that it had consulted with the US Food and Drug Administration (FDA) and took the decision not to pursue the accelerated approval for the lung

Ilumya selectively adheres to the p19 subunit of IL-23 and suppresses its interaction with the IL-23 receptor to inhibit release of pro-inflammatory cytokines and chemokines. It will be

Completion of the acquisition is subject to customary closing conditions, and is expected to close in the second quarter of 2018. Valchlor® is the first and only FDA-approved

The discovery collaboration is based on a new Regeneron publication in the New England Journal of Medicine identifying for the first time a variant in the HSD17B13 gene

RB ended discussions with Pfizer regarding its proposal, which was for part of the business only. Financial Times reported that GlaxoSmithKline (GSK) is now leading the race for Pfizer's

The partnership will focus on developing three proteins, including tau, TDP-43 and an undisclosed target, implicated in the pathogenesis of various neurodegenerative diseases. Celgene will be provided with

Belimumab and rituximab have different but potentially complementary mechanisms of action. This study will assess whether co-administration enhances the treatment effect of belimumab and provides sustained disease control,

The proposed transaction will be completed pursuant to the acquisition by Cipher of all of the outstanding shares of Cardiome, following a restructuring of Cardiome pursuant to a